<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000637730"><TermName>obatoclax</TermName><TermPronunciation>(oh-BA-toh-klax)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of several types of cancer. Obatoclax blocks the actions of certain proteins that cells need to live and it may kill cancer cells. It is a type of apoptosis inducer, a BCL2 protein antagonist, and a BH3 mimetic.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000722824" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;obatoclax&quot;" language="en" id="_3"/><MediaLink ref="CDR0000722823" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;obatoclax&quot;" language="es" id="_4"/><SpanishTermName>obatoclax</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de varios tipos de cáncer.   El obatoclax bloquea las acciones de ciertas proteínas que las células necesitan para vivir y puede destruir células cancerosas.   Es un tipo de inductor de la apoptosis, un antagonista proteico BCL2 y un BH3 mimético.  </DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2009-03-16</DateFirstPublished></GlossaryTerm>
